Search - tctmd.com

Displaying 101 - 120 of 1986

Sort: Relevancy | Date

News Conference News TCT 2024

Few Patients Under 65 Get TAVI: Those Who Do Are Especially Sick

Yael L. Maxwell

November 07, 2024

News Conference News TCT 2024

Co-STAR Hints That Colchicine May Curb Rhythm Disturbances After TAVI

Michael O'Riordan

November 06, 2024

News Conference News TCT 2024

After TAVI, Single Antiplatelet Better Than Dual: TRITAVI Registry

Yael L. Maxwell

November 05, 2024

News Conference News TCT 2024

Vascular Closure via Suture/Plug Combo Reduces Complications: ACCESS-TAVI

Caitlin E. Cox

November 04, 2024

News Opinion Editor's Corner

TCTMD’s Top 10 Most Popular Stories for October 2024

Shelley Wood

November 01, 2024

News Conference News TCT 2024

Pooled All-Female Analysis Support Benefits of TAVI Over SAVR

L.A. McKeown

November 01, 2024

News Conference News TCT 2024

Embolic Protection Benefits Varied by Geography in PROTECTED TAVR

Todd Neale

October 31, 2024

News Conference News TCT 2024

TRISCEND II: Full Results a Win for TTVR in Severe Tricuspid Regurgitation

Michael O'Riordan

October 30, 2024

News Conference News TCT 2024

ACURATE IDE Trial Misses Primary Endpoint in All-Risk TAVI Patients

Todd Neale

October 30, 2024

Presentation TCT 2024

CV Event Reduction is the Essential Criterion for Implementing New Device Therapies

Presenter: Ori Ben-Yehuda

October 30, 2024

Presentation TCT 2024

One-year Outcomes of ACURATE neo2 vs Approved TAVR Devices in All-risk patients with Severe AS: the ACURATE IDE Trial

Presenter: Michael Reardon

October 30, 2024

Presentation TCT 2024

TCT 916: MÉTIS Study: Modification of NEurological Outcome After TAVR UsIng Sentinel Protection Device

Presenter: Tomas Kovarnik

October 30, 2024

Presentation TCT 2024

Left Atrial Appendage Closure with a Novel Fluoropolymer-Coated Device: The HEAL-LAA Post-Approval Clinical Study

Presenter: Seun Alli

October 30, 2024

Presentation TCT 2024

One-Year Follow-Up of the US Early Feasibility Study Evaluating Rotational Closure of the LAA Using the Laminar Device

Presenter: Saibal Kar

October 30, 2024

Presentation TCT 2024

TCT 550: Cardiovascular Outcomes and Comparison of Low vs Intermediate High Hospital Frailty Index on Watchman Device and Associated Readmissions: A Nationwide Readmission Database Analysis

Presenter: Krutarth Pandya

October 30, 2024

Presentation TCT 2024

TCT 549: Association of Left Atrial Appendage Anatomy With Peri-Device Leak at Mid-Term Follow Up

Presenter: Lu Chen

October 30, 2024

Presentation TCT 2024

TCT 846: Association of Cerebral Embolic Protection Device Use With Disabling Stroke After Transcatheter Aortic Valve Replacement: Insights From the National Inpatient Sample

Presenter: Jerry Lipinski

October 30, 2024

Presentation TCT 2024

Technical Enhancements and Case Vignettes from Second Generation TMVR Devices

Presenter: Pradeep Yadav

October 30, 2024

Presentation TCT 2024

Report of an IDE Pivotal Study of a Mechanical Leaflet Splitting Device During TAVR (SHORTCUT)

Presenter: Danny Dvir

October 30, 2024

Presentation TCT 2024

CONTROVERSY: Device Selection and Sizing for TAVR in BAVD

Presenter: Didier Tchetche

October 30, 2024

Advertisement

Few Patients Under 65 Get TAVI: Those Who Do Are Especially Sick

Co-STAR Hints That Colchicine May Curb Rhythm Disturbances After TAVI

After TAVI, Single Antiplatelet Better Than Dual: TRITAVI Registry

Vascular Closure via Suture/Plug Combo Reduces Complications: ACCESS-TAVI

TCTMD’s Top 10 Most Popular Stories for October 2024

Pooled All-Female Analysis Support Benefits of TAVI Over SAVR

Embolic Protection Benefits Varied by Geography in PROTECTED TAVR

TRISCEND II: Full Results a Win for TTVR in Severe Tricuspid Regurgitation

ACURATE IDE Trial Misses Primary Endpoint in All-Risk TAVI Patients

CV Event Reduction is the Essential Criterion for Implementing New Device Therapies

One-year Outcomes of ACURATE neo2 vs Approved TAVR Devices in All-risk patients with Severe AS: the ACURATE IDE Trial

TCT 916: MÉTIS Study: Modification of NEurological Outcome After TAVR UsIng Sentinel Protection Device

Left Atrial Appendage Closure with a Novel Fluoropolymer-Coated Device: The HEAL-LAA Post-Approval Clinical Study

One-Year Follow-Up of the US Early Feasibility Study Evaluating Rotational Closure of the LAA Using the Laminar Device

TCT 550: Cardiovascular Outcomes and Comparison of Low vs Intermediate High Hospital Frailty Index on Watchman Device and Associated Readmissions: A Nationwide Readmission Database Analysis

TCT 549: Association of Left Atrial Appendage Anatomy With Peri-Device Leak at Mid-Term Follow Up

TCT 846: Association of Cerebral Embolic Protection Device Use With Disabling Stroke After Transcatheter Aortic Valve Replacement: Insights From the National Inpatient Sample

Technical Enhancements and Case Vignettes from Second Generation TMVR Devices

Report of an IDE Pivotal Study of a Mechanical Leaflet Splitting Device During TAVR (SHORTCUT)

CONTROVERSY: Device Selection and Sizing for TAVR in BAVD

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content